Shares of Marker Therapeutics, Inc. (MRKR) rose by 23% on Monday after the company announced a clinical update concerning the APOLLO study, with the study participant tolerating the initial dose level well and remaining in complete response six months after MT-601 treatment MRKR is trading on the Nasdaq at $4.